<b>Results:</b> We show that systemic administration of mesenchymal stem cell (MSC)-derived apoptotic vesicles (MSC-apoVs) can ameliorate impaired ovarian folliculogenesis, PCOS phenotype, and reduced birth rate in <i>Fas<sup>mut</sup></i> and <i>FasL<sup>mut</sup></i> mice. Here, FAS is linked to polycystic ovary syndrome.